Skandinaviska Enskilda Banken (SEB)
SCLN

Skandinaviska Enskilda Banken (SEB)’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-256,200
Closed -$2.87M – 745
2017
Q3 		$2.87M Hold
256,200
– – 0.03% 390
2017
Q2 		$2.82M Buy
256,200
+7,700
+3% +$77K 0.03% 397
2017
Q1 		$2.44M Buy
248,500
+91,700
+58% +$916K 0.02% 404
2016
Q4 		$1.69M Buy
156,800
+20,900
+15% +$209K 0.02% 401
2016
Q3 		$1.39M Sell
135,900
-130,400
-49% -$1.42M 0.02% 548
2016
Q2 		$3.48M Sell
266,300
-143,400
-35% -$1.88M 0.04% 322
2016
Q1 		$4.51M Sell
409,700
-293,200
-42% -$2.61M 0.05% 259
2015
Q4 		$6.47M Buy
+702,900
New +$5.88M 0.08% 183

Skandinaviska Enskilda Banken (SEB)'s SCLN Position: Q4 2017 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 256,200 shares — an estimated $2.87M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in SCLN in Q4 2015 and held it in 8 quarters. The position peaked at $6.47M in Q4 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 256,200 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $2.87M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 8 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Sciclone Pharmaceuticals Inc position peaked at $6.47M in Q4 2015.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2017, filed 12 Feb 2018.